109 related articles for article (PubMed ID: 38843774)
1. Iminoamido chelated iridium(III) and ruthenium(II) anticancer complexes with mitochondria-targeting ability and potential to overcome cisplatin resistance.
Guo L; Li P; Jing Z; Gong Y; Lai K; Fu H; Dong H; Yang Z; Liu Z
J Inorg Biochem; 2024 Jun; 258():112631. PubMed ID: 38843774
[TBL] [Abstract][Full Text] [Related]
2. Half-Sandwich Iridium(III), Rhodium(III), and Ruthenium(II) Complexes Chelating Hybrid sp
Guo L; Li P; Li J; Gong Y; Li X; Liu Y; Yu K; Liu Z
Inorg Chem; 2023 Sep; 62(37):15118-15137. PubMed ID: 37671819
[TBL] [Abstract][Full Text] [Related]
3. Potent Half-Sandwich 16-/18-Electron Iridium(III) and Ruthenium(II) Anticancer Complexes with Readily Available Amine-Imine Ligands.
Guo L; Li P; Li J; Gong Y; Li X; Wen T; Wu X; Yang X; Liu Z
Inorg Chem; 2023 Dec; 62(51):21379-21395. PubMed ID: 38096360
[TBL] [Abstract][Full Text] [Related]
4. Mitochondria-targeted neutral and cationic iridium(III) anticancer complexes chelating simple hybrid sp
Li P; Guo L; Li J; Yang Z; Fu H; Lai K; Dong H; Fan C; Liu Z
Dalton Trans; 2024 Jan; 53(5):1977-1988. PubMed ID: 38205595
[TBL] [Abstract][Full Text] [Related]
5. Novel and Versatile Imine-N-Heterocyclic Carbene Half-Sandwich Iridium(III) Complexes as Lysosome-Targeted Anticancer Agents.
Yang Y; Guo L; Tian Z; Gong Y; Zheng H; Zhang S; Xu Z; Ge X; Liu Z
Inorg Chem; 2018 Sep; 57(17):11087-11098. PubMed ID: 30133276
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial targeting half-sandwich iridium(III) and ruthenium(II) dppf complexes and in vitro anticancer assay.
Liu J; Wu Y; Yang G; Liu Z; Liu X
J Inorg Biochem; 2023 Feb; 239():112069. PubMed ID: 36423395
[TBL] [Abstract][Full Text] [Related]
7. Serendipitous Synthesis of Five-Coordinated Half-Sandwich Aminoimine Iridium(III) and Ruthenium(II) Complexes and Their Application as Potent Anticancer Agents.
Du Q; Guo L; Ge X; Zhao L; Tian Z; Liu X; Zhang F; Liu Z
Inorg Chem; 2019 May; 58(9):5956-5965. PubMed ID: 30986046
[TBL] [Abstract][Full Text] [Related]
8. Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features.
Li J; Tian M; Tian Z; Zhang S; Yan C; Shao C; Liu Z
Inorg Chem; 2018 Feb; 57(4):1705-1716. PubMed ID: 29400963
[TBL] [Abstract][Full Text] [Related]
9. Highly potent half-sandwich iridium and ruthenium complexes as lysosome-targeted imaging and anticancer agents.
Li J; Tian Z; Xu Z; Zhang S; Feng Y; Zhang L; Liu Z
Dalton Trans; 2018 Nov; 47(44):15772-15782. PubMed ID: 30357192
[TBL] [Abstract][Full Text] [Related]
10. Half-Sandwich Iridium and Ruthenium Complexes: Effective Tracking in Cells and Anticancer Studies.
Li J; Guo L; Tian Z; Zhang S; Xu Z; Han Y; Li R; Li Y; Liu Z
Inorg Chem; 2018 Nov; 57(21):13552-13563. PubMed ID: 30289251
[TBL] [Abstract][Full Text] [Related]
11. Potential anticancer agent for selective damage to mitochondria or lysosomes: Naphthalimide-modified fluorescent biomarker half-sandwich iridium (III) and ruthenium (II) complexes.
Ma W; Zhang S; Tian Z; Xu Z; Zhang Y; Xia X; Chen X; Liu Z
Eur J Med Chem; 2019 Nov; 181():111599. PubMed ID: 31408807
[TBL] [Abstract][Full Text] [Related]
12. Increasing Anticancer Activity with Phosphine Ligation in Zwitterionic Half-Sandwich Iridium(III), Rhodium(III), and Ruthenium(II) Complexes.
Hu X; Guo L; Liu M; Zhang Q; Gong Y; Sun M; Feng S; Xu Y; Liu Y; Liu Z
Inorg Chem; 2022 Dec; 61(49):20008-20025. PubMed ID: 36426422
[TBL] [Abstract][Full Text] [Related]
13. Configurationally regulated half-sandwich iridium(III)-ferrocene heteronuclear metal complexes: Potential anticancer agents.
Liu X; Wang Z; Zhang X; Lv X; Sun Y; Dong R; Li G; Ren X; Ji Z; Yuan XA; Liu Z
J Inorg Biochem; 2023 Dec; 249():112393. PubMed ID: 37806004
[TBL] [Abstract][Full Text] [Related]
14. Imine-N-Heterocyclic Carbenes as Versatile Ligands in Ruthenium(II) p-Cymene Anticancer Complexes: A Structure-Activity Relationship Study.
Yang Y; Guo L; Tian Z; Liu X; Gong Y; Zheng H; Ge X; Liu Z
Chem Asian J; 2018 Oct; 13(19):2923-2933. PubMed ID: 30101417
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and evaluation of fluorine and Naphthyridine-Based half-sandwich organoiridium/ruthenium complexes with bioimaging and anticancer activity.
Li J; Tian Z; Ge X; Xu Z; Feng Y; Liu Z
Eur J Med Chem; 2019 Feb; 163():830-839. PubMed ID: 30579123
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationships for highly potent half-sandwich organoiridium(III) anticancer complexes with C^N-chelated ligands.
Yang Y; Guo L; Ge X; Shi S; Gong Y; Xu Z; Zheng X; Liu Z
J Inorg Biochem; 2019 Feb; 191():1-7. PubMed ID: 30445339
[TBL] [Abstract][Full Text] [Related]
17. Cyclometalated Ru(II)-isoquinoline complexes overcome cisplatin resistance of A549/DDP cells by downregulation of Nrf2 via Akt/GSK-3β/Fyn pathway.
Chen L; Wang J; Cai X; Chen S; Zhang J; Li B; Chen W; Guo X; Luo H; Chen J
Bioorg Chem; 2022 Feb; 119():105516. PubMed ID: 34856444
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, characterization, anticancer efficacy evaluation of ruthenium(II) and iridium(III) polypyridyl complexes toward A549 cells.
Liang L; Yang Y; Liu H; Yuan F; Yuan Y; Li W; Huang C; Chen J; Liu Y
J Biol Inorg Chem; 2023 Jun; 28(4):421-437. PubMed ID: 37097484
[TBL] [Abstract][Full Text] [Related]
19.
Komarnicka UK; Niorettini A; Kozieł S; Pucelik B; Barzowska A; Wojtala D; Ziółkowska A; Lesiów M; Kyzioł A; Caramori S; Porchia M; Bieńko A
Pharmaceuticals (Basel); 2022 Jan; 15(2):. PubMed ID: 35215281
[TBL] [Abstract][Full Text] [Related]
20. Cyclometalated ruthenium complexes overcome cisplatin resistance through PI3K/mTOR/Nrf2 signaling pathway.
Chen L; Yu W; Tang H; Zhang S; Wang J; Ouyang Q; Guo M; Zhu X; Huang Z; Chen J
Metallomics; 2024 Jan; 16(1):. PubMed ID: 38183290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
